ADC Therapeutics SA has released a corporate presentation highlighting its advancements and strategic direction in the field of antibody-drug conjugates (ADCs). The company emphasizes its specialized end-to-end capabilities from discovery to commercialization, aiming to enhance the therapeutic index of next-generation ADCs through an array of payloads, linkers, and conjugation chemistry. A key focus is on the expansion of the FDA-approved ZYNLONTA® for diffuse large B-cell lymphoma (DLBCL), including potential new indications and combination therapies. Additionally, ADC Therapeutics is pursuing early-stage development in solid tumors, targeting Claudin-6, PSMA, NaPi2b, and ASCT2. The company is also seeking research collaborations to broaden its portfolio. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。